Back to Trades
DeLong Mark Jeffrey
InsiderCIK 0001856078
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 6
- Buy transactions
- 0
- Sell transactions
- 4
- Companies
- 1
- Active
- 2026
DeLong Mark Jeffrey has filed 6 SEC reports (2026), all concentrated in Apellis Pharmaceuticals, Inc. (APLS), totaling $8.7M in disclosed volume. Weighing $0 bought versus $147.4K sold, the history is heavily weighted toward selling. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
6 loaded
| May 14 | APLS Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Insider | Grant | $8.5M |
| Feb 13 | APLS Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | $8.2K |
| Jan 30 | APLS Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | Grant | $0 |
| Jan 23 | APLS Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | $73.4K |
| Jan 21 | APLS Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | $26.4K |
| Jan 15 | APLS Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | $39.5K |
6 filings